Our CEO Susan Greenfield and Operations Direction Sara Garcia-Rates, joined Xenopat for a face-to-face meeting in Barcelona where they shared the progress made for the Tecniospring Industry project “Development of a T14 Inhibitor for Treatment of ColoRectal Cancer”, and explored the possibilities for future projects that could sprout from this collaboration.